All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
Equity

Stentys €40m rights issue lets FSI and funds in

Stentys, a biotechnology company with a focus on heart problems, launched a €36.4m rights issue on Tuesday, which will allow for a reorganisation of shareholders with the French Fonds Stratégique d’Investissement (FSI) joining the register.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree